Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration
Corticobasal degeneration (CBD) is characterized by 4-repeat misfolded tau (4Rtau) including astrocytic plaques, threads, and neuronal tangles . 18F-AV-1451 is a PET radioligand that achieves in vivo binding in Alzheimer’s disease (AD)  and autoradiographic evidence of binding to paired helical filaments (PHFs) composed of 3-repeat misfolded tau (3Rtau) and 4Rtau characteristic of AD histopathology [4, 5, 7]. However, autoradiographic studies of 18F-AV-1451 on CBD postmortem tissue failed to demonstrate binding in cortical regions [5, 7], though there was minimal pathology in one study (<1.1 % tau-load) . Another study suggests minimal, but present, autoradiographic binding of 18F-AV-1451 for 4Rtau . Given mixed autoradiographic evidence in CBD, there is a need for in vivo evaluations of 18F-AV-1451 in patients with pathological confirmation.
We report a multimodal evaluation of a 58-year-old male with autopsy-confirmed CBD. He participated in in vivo baseline (15 months...
KeywordsGrey Matter Volume Globus Pallidus Progressive Supranuclear Palsy Corticobasal Degeneration Deep Grey Matter
This work was supported in part by the National Institutes of Health (NIH; AG043503; AG017586; AG10124) and the Dana Foundation. PET imaging data acquisition was supported by AVID Radiopharmaceuticals (Philadelphia, PA, USA), a wholly owned subsidiary of Eli Lilly and Company.
- 7.Sander K, Lashley T, Gami P, Gendron T, Lythgoe MF, Rohrer JD, et al (2016) Characterization of tau positron emission tomography tracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other dementias. Alzheimers Dement. doi: 10.1016/j.jalz.2016.01.003 PubMedGoogle Scholar